AbbVie (ABBV)
(Delayed Data from NYSE)
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.91 +0.44 (0.22%) 4:46 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$200.47 USD
-3.08 (-1.51%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $200.91 +0.44 (0.22%) 4:46 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Analyst Reports for Union Pacific, AbbVie & U.S. Bancorp
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and U.S. Bancorp (USB).
Roche (RHHBY) to Terminate Pacifica Bioscience Agreement
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it intends to terminate its agreement with Pacifica Bioscience.
Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls
by Zacks Equity Research
Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.
Roche/AbbVie's Leukemia Drug Venclyxto Gains EU Approval
by Zacks Equity Research
Roche (RHHBY) and AbbVie's (ABBV) Venclyxto has gained EU approval for the treatment of appropriate patients with hard-to-treat chronic lymphocytic leukemia.
AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.
Amgen/Allergan File for EU Approval of Avastin Biosimilar
by Zacks Equity Research
Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.
AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.
Momenta/Shire's Humira Biosimilar Meets Study Objective
by Zacks Equity Research
Momenta (MNTA) announced positive data from a phase III study on M923 for the treatment of moderate-to-severe chronic plaque psoriasis.
The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
Top Research Reports for Cisco, Amgen & NextEra Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Cisco (CSCO) and NextEra Energy (NEE).
Pharma Industry Outlook - November 2016
by Arpita Dutt
It's been a rough year for pharma and biotech stocks, with media and political focus on the high price of drugs, mixed performance results, slower-than-expected new product launches and increasing competition.
Timeout from Q3 Earnings: GDP +2.9%
by Mark Vickery
With GDP at 2.9% in Q3 (first read), we are seeing a snap-back from below-trend growth earlier in the year.
Stock Research Reports for Amazon, Boeing & MasterCard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), MasterCard (MA) and Boeing (BA).
How Value Investors Can Buy Growth
by Tracey Ryniec
Value and growth is a magical combination. Here???s how to get it.
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
by Sheraz Mian
Today's must-read reports are for AbbVie (ABBV), Morgan Stanley (MS) and Union Pacific (UNP).
5 Biotech Stocks to Bet on This Earnings Season
by Zacks Equity Research
The happening biotech sector should be a good bet for investors.
Stock Market News for April 07, 2016
by Zacks Equity Research
Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks